Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who has been receiving a stable dose and regimen of insulin over 12 weeks before administration of investigational dug~* Patients who are under dietary management and taking therapeutic exercise for diabetes over 12 weeks before administration of investigational drug~* Patients with HbA1c of ≥7.5% and \<10.5%~* Patients who were not administered diabetes therapeutic drugs prohibited for concomitant use within 12 weeks before administration of investigational drug~Exclusion Criteria:~* Patients with type 1 diabetes mellitus, diabetes mellitus resulting from pancreatic disorder, or secondary diabetes mellitus (Cushing's syndrome, acromegaly, etc.)~* Patients with severe diabetic complications (proliferative diabetic retinopathy, stage 4 nephropathy, or serious diabetic neuropathy)~* Patients with hereditary glucose-galactose malabsorption or primary renal glucosuria~* Patients with systolic blood pressure of ≥160 mmHg or diastolic blood pressure of ≥100 mmHg~* Patients with serious renal or hepatic disease~* Patients with eGFR of \<45 mL/min/1.73 m2~* Patients who are the excessive alcohol addicts~* Patients who are pregnant, lactating and probably pregnant patients and patients who can not agree to contraception

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Canagliflozin (TA-7284) ＋insulin (Type: EXPERIMENTAL): None
- Placebo＋insulin (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).